Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.66 |
| ▸ | RXRA | P19793 | 2/20 | 0.62 |
| ▸ | RXRB | P28702 | 2/20 | 0.62 |
| ▸ | ERN1 | O75460 | 2/20 | 0.56 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410738 | 1.00 | KMO (0.66) | KMORXRARXRBERN1MAP2K4 | |
| SCHEMBL121809 | 0.90 | KMO (0.68) | KMORXRARXRBERN1MAP2K4 | |
| SCHEMBL30189265 | 0.87 | KMO (0.53) | KMORXRARXRBDHODHDCLRE1B | |
| SCHEMBL2160048 | 0.87 | KMO (0.53) | KMORXRARXRBDHODHDCLRE1B | |
| SCHEMBL10012987 | 0.86 | KMO (0.79) | KMORXRARXRBERN1DHODH | |
| SCHEMBL16429234 | 0.86 | KMO (0.87) | KMORXRARXRBERN1DHODH | |
| SCHEMBL71238 | 0.85 | KMO (0.86) | KMORXRARXRBERN1KEAP1 | |
| SCHEMBL30725957 | 0.85 | KMO (0.86) | KMORXRARXRBERN1KEAP1 | |
| SCHEMBL29904709 | 0.85 | KMO (0.86) | KMORXRARXRBERN1KEAP1 | |
| SCHEMBL3210250 | 0.85 | KMO (0.60) | KMORXRARXRBERN1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | KMO 2815/4885RXRA 4515/4885RXRB 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.